Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.31 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577871 | 0.86 | USP2 (0.39) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4579147 | 0.81 | CHRNB2 (0.45) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4577660 | 0.77 | KMT2A (0.52) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL15223172 | 0.75 | USP2 (0.38) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6732293 | 0.72 | ALDH1A1 (0.64) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL16798146 | 0.71 | ALDH1A1 (0.56) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL146290 | 0.70 | — | — | |
| SCHEMBL525215 | 0.70 | ALDH1A1 (0.61) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4578522 | 0.69 | TSHR (0.49) | USP2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL27742503 | 0.69 | MALT1 (0.30) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | USP2 2716/4885MEN1 1070/4885KMT2A 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.